In the pharmaceutical industry, you can find stocks that double in value in one day. Onyx Pharmaceuticals
Onyx and partner Bayer
Even more importantly, the Food and Drug Administration had already said this primary endpoint was valid for the special protocol assessment, or special agreement, for this clinical trial. This in no way guarantees that the FDA will approve Nexavar to treat liver cancer. But combine this with the facts that Onyx said that the drug produced no differences in serious adverse events compared with the placebo and there are zero other approved treatments for this indication, and Nexavar is close to a lock for approval.
Onyx suffered a setback with Nexavar in November when there were disappointing results in trials for it as a treatment for advanced melanoma, but the drug is approved to treat advanced kidney cancer, where it competes primarily with Pfizer's
The additional market for Nexavar to treat liver cancer is in the hundreds of millions of dollars, because no other drugs are approved for that cancer, which is the fifth-most common one in the U.S. with more than 19,000 new cases annually, according to the National Cancer Institute. Onyx gave no timelines but said an application to market the drug will be filed with the FDA and European Union authorities as soon as possible.
Nexavar is in various stages of clinical study for several different cancers. Despite the recent good news, and as the data in December and from other targeted therapies has shown, positive trial results for one type of cancer do not mean the drug will work for other types. This is something investors might want to consider when taking a closer look at Onyx.
Need new ideas for your money? Investors like you rate thousands of stocks on Motley Fool CAPS to help you with your own stock selections. It's fun --and it's free.
Fool contributor Brian Lawler has a great rock collection but does not own shares of Onyx or any other company mentioned in this article. Pfizer is an Inside Value recommendation. The Fool has a disclosure policy.
More from The Motley Fool
3 Signs We Could Be Entering a Biotech Bubble
Three ominous warning signs could signal a dramatic reversal is on the way for the biotech sector.
This Week in Biotech
A mammoth buyout, positive clinical data, a new drug filing, and yet another disappointment for one biotech are this week's biggest news stories.
Onyx, Bayer Expect Nexavar Decision by Christmas Day
Priority review bumps up FDA's timeline.